Skip to main content
. 2014 Dec 15;1(12):844–853. doi: 10.18632/oncoscience.106

Figure 2. Sunitinib concentrations in tumors, skin and serum.

Figure 2

Sunitinib concentrations at the end of the experiment in mice bearing HT-29 parental (HT-29PAR) or HT-29 sunitinib resistant (HT-29SUN) tumors. Sunitinib concentrations intratumoral (A), in skin (B) and in serum (C) were measured with liquid chromatography - tandem mass spectrometry (LC-MS/MS). Results are shown as individual mice (n = 8) with median indicated.